taxonomy (1)
protein (1)
source (7)
structure (55)
composition (61)
disease (4)
reference (18)
site (6)
peptide (20)
- Homo sapiens (Human)
Taxonomy
- Serotransferrin / Homo sapiens P02787
Protein
- Amniotic Fluid (UBERON_0000173)
- Blood Plasma (UBERON_0001969)
- Blood Serum (UBERON_0001977)
- Mammary Gland (UBERON_0001911)
- Urine (UBERON_0001088)
- BTI-Tn-5B1-4 (CVCL_C190) Egg Cell
- Cerebrospinal Fluid Secretion (GO_0033326)
Source
- O-Linked / Core 1 / Gal(b1-3)GalNAc
- O-Linked / Core 1 / NeuAc(a2-3)Gal(b1-3)GalNAc
- N-Linked / No-core / Man(a1-6)Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc
- N-Linked / Pauci-Mannose / Man(a1-3)[Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Pauci-Mannose / Man(a1-3)[Man(a1-6)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc
- N-Linked / Complex / GlcNAc(b1-2)Man(a1-3)[Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Pauci-Mannose / Man(a1-3)[Man(a1-6)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-3)][Fuc(a1-6)]GlcNAc
- N-Linked / High-Mannose / Man(a1-3)[Man(a1-6)]Man(a1-6)[Man(a1-3)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / GlcNAc(b1-2)Man(a1-3)[Man(a1-6)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc
- N-Linked / Complex / GlcNAc(b1-2)Man(a1-6)[Man(a1-3)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc
- N-Linked / Complex / Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / High-Mannose / Man(a1-2)Man(a1-3)[Man(a1-6)]Man(a1-6)[Man(a1-3)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / High-Mannose / Man(a1-3)[Man(a1-6)]Man(a1-6)[Man(a1-2)Man(a1-3)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[Man(a1-6)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc
- N-Linked / Complex / Structure 2011
- N-Linked / High-Mannose / Man(a1-2)Man(a1-2)Man(a1-3)[Man(a1-3)[Man(a1-6)]Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / High-Mannose / Man(a1-2)Man(a1-6)[Man(a1-3)]Man(a1-6)[Man(a1-2)Man(a1-3)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / NeuAc(?2-?)Gal(?1-?)GlcNAc(?1-?)Man(a1-3)[Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[Man(a1-6)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-3)][Fuc(a1-6)]GlcNAc
- N-Linked / Complex / Gal(?1-?)GlcNAc(?1-?)Man(a1-3)[Gal(?1-?)GlcNAc(?1-?)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / GlcNAc(b1-2)Man(a1-3)[GlcNAc(b1-2)Man(a1-6)][GlcNAc(b1-4)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc
- N-Linked / High-Mannose / Man(a1-2)Man(a1-3)[Man(a1-6)]Man(a1-6)[Man(a1-2)Man(a1-2)Man(a1-3)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / High-Mannose / Man(a1-2)Man(a1-6)[Man(a1-3)]Man(a1-6)[Man(a1-2)Man(a1-2)Man(a1-3)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / Fuc(?1-?)[Gal(?1-?)]GlcNAc(?1-?)Man(a1-?)[Gal(?1-?)GlcNAc(?1-?)Man(a1-?)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / Gal(?1-?)GlcNAc(?1-?)Man(a1-3)[Gal(?1-?)GlcNAc(?1-?)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)[Fuc(?1-?)]GlcNAc
- N-Linked / Complex / Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc
- N-Linked / Complex / Structure 3041
- N-Linked / High-Mannose / Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-6)]Man(a1-6)[Man(a1-2)Man(a1-2)Man(a1-3)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)Man(a1-6)[Gal(b1-4)GlcNAc(b1-2)Man(a1-3)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-?)[Gal(b1-4)GlcNAc(b1-2)Man(a1-?)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[Gal(b1-4)GlcNAc(b1-2)Man(a1-6)][GlcNAc(b1-4)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc
- N-Linked / Complex / Structure 644
- N-Linked / Complex / Gal(?1-?)GlcNAc(?1-?)[Gal(?1-?)GlcNAc(?1-?)]Man(a1-?)[Gal(?1-?)GlcNAc(?1-?)Man(a1-?)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / High-Mannose / Glc(a1-3)Man(a1-2)Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-6)]Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc
- N-Linked / Complex / Gal(?1-?)GlcNAc(?1-?)[Gal(?1-?)GlcNAc(?1-?)]Man(a1-?)[Gal(?1-?)GlcNAc(?1-?)Man(a1-?)]Man(b1-4)GlcNAc(b1-4)[Fuc(?1-?)]GlcNAc
- N-Linked / Complex / NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)Man(a1-6)[NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-3)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)Man(a1-?)[NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-?)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / Gal(?1-?)GlcNAc(?1-?)[Gal(?1-?)GlcNAc(?1-?)]Man(a1-?)[Gal(?1-?)GlcNAc(?1-?)Man(a1-?)]Man(b1-4)GlcNAc(b1-4)GlcNAc+"+ NeuAc(a2-6)"
- N-Linked / Complex / NeuAc(?2-?)Gal(?1-?)GlcNAc(?1-?)Man(a1-3)[NeuAc(?2-?)Gal(?1-?)GlcNAc(?1-?)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)[Fuc(?1-?)]GlcNAc
- N-Linked / Complex / NeuAc(a2-3)Gal(b1-4)[Fuc(a1-3)]GlcNAc(b1-2)Man(a1-6)[NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-3)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)Man(a1-6)[NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-3)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc
- N-Linked / Complex / NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc
- N-Linked / Complex / NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-4)[NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)]Man(a1-3)[NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-4)[NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)]Man(a1-3)[NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-6)[NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)]Man(a1-6)[NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-3)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)[NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-4)]Man(a1-3)[NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / NeuAc(a2-3)Gal(b1-4)[Fuc(a1-3)]GlcNAc(b1-4)[NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)]Man(a1-3)[NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / NeuAc(a2-3)Gal(b1-4)[Fuc(a1-3)]GlcNAc(b1-4)[NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)]Man(a1-3)[NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-4)[NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)]Man(a1-3)[NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc
Reported structure
- Hex:1 (avg mass : 180.1577 )
- Hex:1 HexNAc:1 (avg mass : 383.3527 )
- Hex:1 HexNAc:1 NeuAc:1 (avg mass : 674.6106 )
- Hex:2 HexNAc:2 dHex:1 (avg mass : 894.8331 )
- Hex:3 HexNAc:2 (avg mass : 910.8325 )
- Hex:3 HexNAc:2 dHex:1 (avg mass : 1056.9755 )
- Hex:3 HexNAc:2 dHex:2 (avg mass : 1203.1185 )
- Hex:3 HexNAc:3 (avg mass : 1114.0275 )
- Hex:3 HexNAc:3 dHex:1 (avg mass : 1260.1705 )
- Hex:3 HexNAc:5 dHex:1 (avg mass : 1666.5605 )
- Hex:3 HexNAc:6 dHex:1 NeuAc:1 (avg mass : 2161.0134 )
- Hex:3 HexNAc:6 dHex:1 NeuAc:2 (avg mass : 2452.2713 )
- Hex:3 HexNAc:7 (avg mass : 1926.8075 )
- Hex:4 HexNAc:3 (avg mass : 1276.1699 )
- Hex:4 HexNAc:3 NeuAc:1 (avg mass : 1567.4278 )
- Hex:4 HexNAc:3 dHex:1 (avg mass : 1422.3129 )
- Hex:4 HexNAc:3 dHex:2 (avg mass : 1568.4559 )
- Hex:4 HexNAc:4 (avg mass : 1479.3649 )
- Hex:4 HexNAc:4 NeuAc:1 (avg mass : 1770.6228 )
- Hex:4 HexNAc:4 dHex:1 NeuAc:1 (avg mass : 1916.7658 )
- Hex:4 HexNAc:4 dHex:2 (avg mass : 1771.6509 )
- Hex:4 HexNAc:4 dHex:2 NeuAc:1 (avg mass : 2062.9088 )
- Hex:4 HexNAc:5 NeuAc:1 NeuGc:1
- Hex:4 HexNAc:5 dHex:2 NeuAc:1 (avg mass : 2266.1038 )
- Hex:4 HexNAc:6 dHex:1 (avg mass : 2031.8979 )
- Hex:4 HexNAc:6 dHex:2 (avg mass : 2178.0409 )
- Hex:4 HexNAc:9
- Hex:5 HexNAc:2 (avg mass : 1235.1173 )
- Hex:5 HexNAc:4 (avg mass : 1641.5073 )
- Hex:5 HexNAc:4 NeuAc:1 (avg mass : 1932.7652 )
- Hex:5 HexNAc:4 NeuAc:1 NeuGc:1 (avg mass : 2240.0225 )
- Hex:5 HexNAc:4 NeuAc:2 (avg mass : 2224.0231 )
- Hex:5 HexNAc:4 dHex:1 (avg mass : 1787.6503 )
- Hex:5 HexNAc:4 dHex:1 NeuAc:1 (avg mass : 2078.9082 )
- Hex:5 HexNAc:4 dHex:1 NeuAc:2 (avg mass : 2370.1661 )
- Hex:5 HexNAc:4 dHex:2 NeuAc:1 (avg mass : 2225.0512 )
- Hex:5 HexNAc:5 NeuAc:1 (avg mass : 2135.9602 )
- Hex:5 HexNAc:5 dHex:1 (avg mass : 1990.8453 )
- Hex:5 HexNAc:5 dHex:1 NeuAc:2 (avg mass : 2573.3611 )
- Hex:5 HexNAc:6 dHex:1 (avg mass : 2194.0403 )
- Hex:6 HexNAc:2 (avg mass : 1397.2597 )
- Hex:6 HexNAc:4 NeuAc:1 (avg mass : 2094.9076 )
- Hex:6 HexNAc:4 NeuAc:2 (avg mass : 2386.1655 )
- Hex:6 HexNAc:4 dHex:1 (avg mass : 1949.7927 )
- Hex:6 HexNAc:4 dHex:1 NeuAc:1 (avg mass : 2241.0506 )
- Hex:6 HexNAc:4 dHex:2 (avg mass : 2095.9357 )
- Hex:6 HexNAc:5 (avg mass : 2006.8447 )
- Hex:6 HexNAc:5 NeuAc:1 (avg mass : 2298.1026 )
- Hex:6 HexNAc:5 NeuAc:2 (avg mass : 2589.3605 )
- Hex:6 HexNAc:5 NeuAc:3 (avg mass : 2880.6184 )
- Hex:6 HexNAc:5 dHex:1 (avg mass : 2152.9877 )
- Hex:6 HexNAc:5 dHex:1 NeuAc:2 (avg mass : 2735.5035 )
- Hex:6 HexNAc:5 dHex:1 NeuAc:3 (avg mass : 3026.7614 )
- Hex:6 HexNAc:6 (avg mass : 2210.0397 )
- Hex:7 HexNAc:2 (avg mass : 1559.4021 )
- Hex:7 HexNAc:9 dHex:1 NeuAc:1
- Hex:7 HexNAc:9 dHex:1 NeuAc:2
- Hex:8 HexNAc:2 (avg mass : 1721.5445 )
- Hex:9 HexNAc:2 (avg mass : 1883.6869 )
- Hex:10 HexNAc:2 (avg mass : 2045.8293 )
- Hex:12 HexNAc:2 (avg mass : 2370.1141 )
Composition
- Cancer, breast (DOID:1612)
- Carbohydrate-Deficient Glycoprotein Syndrome, Type II (DOID:5212)
- Carcinoma, Hepatocellular (DOID:684)
- Prostate cancer (DOID:10283)
Disease
- Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
- Distinct urinary glycoprotein signatures in prostate cancer patients (2018 - Rebeca Kawahara, Fabio Ortega, Livia Rosa-Fernandes, Vanessa Guimarães, Daniel Quina, Willian Nahas, Veit Schwämmle, Miguel Srougi, Katia R.M. Leite, Morten Thaysen-Andersen, Martin R. Larsen and Giuseppe Palmisano) / Status : Unreviewed
- Large-scale intact glycopeptide identification by Mascot database search (2018 - Ravi Chand Bollineni, Christian Jeffrey Koehler, Randi Elin Gislefoss, Jan Haug Anonsen, Bernd Thiede) / Status : Unreviewed
- Site-Specific Profiling of Serum Glycoproteins Using N-Linked Glycan and Glycosite Analysis Revealing Atypical N-Glycosylation Sites on Albumin and α-1B-Glycoprotein (2018 - Shisheng Sun, Yingwei Hu, Li Jia, Shadi Toghi Eshghi, Yang Liu, Punit Shah, Hui Zhang) / Status : Unreviewed
- Selective glycopeptide profiling by acetone enrichment and LC/MS (2014 - Takakura D, Harazono A, Hashii N, Kawasaki N) / Status : Reviewed
- Glycomic analysis of high density lipoprotein shows a highly sialylated particle (2014 - Huang J1, Lee H, Zivkovic AM, Smilowitz JT, Rivera N, German JB, Lebrilla CB) / Status : Reviewed
- Confident assignment of site-specific glycosylation in complex glycoproteins in a single step (2014 - Khatri K, Staples GO, Leymarie N, Leon DR, Turiák L, Huang Y, Yip S, Hu H, Heckendorf CF, Zaia J.) / Status : Reviewed
- Comparison of sialylated N-glycopeptide levels in serum of pancreatic cancer patients, acute pancreatitis patients, and healthy controls (2014 - Kontro H, Joenväärä S, Haglund C, Renkonen R) / Status : Reviewed
- Enrichment of glycopeptides for glycan structure and attachment site identification (2009 - Nilsson J, Rüetschi U, Halim A, Hesse C, Carlsohn E, Brinkmalm G, Larson G.) / Status : Reviewed
- Simultaneous glycosylation analysis of human serum glycoproteins by high-performance liquid chromatography/tandem mass spectrometry (2008 - Harazono A, Kawasaki N, Itoh S, Hashii N, Matsuishi-Nakajima Y, Kawanishi T, Yamaguchi T) / Status : Reviewed
- N-glycan patterns of human transferrin produced in Trichoplusia ni insect cells: effects of mammalian galactosyltransferase. (2000 - Ailor E, Takahashi N, Tsukamoto Y, Masuda K, Rahman B, Jarvis D, Lee Y, Betenbaugh M) / Status : Reviewed
- X-ray crystallography and mass spectroscopy reveal that the N-lobe of human transferrin expressed in Pichia pastoris is folded correctly but is glycosylated on serine-32. (1999 - Bewley M, Tam B, Grewal J, He S, Shewry S, Murphy M, Mason A, Woodworth R, Baker E, MacGillivray R) / Status : Reviewed
- Expression of N-linked sialyl Le(x) determinants and O-glycans in the carbohydrate moiety of human amniotic fluid transferrin during pregnancy. (1998 - van Rooijen J, Jeschke U, Kamerling J, Vliegenthart J) / Status : Reviewed
- Two-dimensional chromatography in the analysis of complex glycans from transferrin. (1998 - Charlwood J, Birrell H, Tolson D, Camilleri P) / Status : Reviewed
- 'Brain-type' N-glycosylation of asialo-transferrin from human cerebrospinal fluid. (1995 - Hoffmann A, Nimtz M, Getzlaff R, Conradt H) / Status : Reviewed
- Carbohydrate deficient glycoprotein syndrome type II: a deficiency in Golgi localised N-acetyl-glucosaminyltransferase II. (1994 - Jaeken J, Schachter H, Carchon H, De Cock P, Coddeville B, Spik G) / Status : Reviewed
- Alteration of asparagine-linked glycosylation in serum transferrin of patients with hepatocellular carcinoma. (1994 - Matsumoto K, Maeda Y, Kato S, Yuki H) / Status : Reviewed
- N-glycosylation site mapping of human serotransferrin by serial lectin affinity chromatography, fast atom bombardment-mass spectrometry, and 1H nuclear magnetic resonance spectroscopy. (1992 - Fu D, van Halbeek H) / Status : Reviewed
Reference
- Serotransferrin / Homo sapiens
Reported glycosite
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVKK (33aa)
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVKK (33aa)
- CGIVPVIAENYNK (13aa)
- KCGLVPVLAENYNK (14aa)
- CGLVPVLAENYNK (13aa)
- LAENYNK (7aa)
- GLVPVLAENYNK (12aa)
- CGLVPVLAENYNKSDNCEDTPEAGYF (26aa)
- LCMGSGLNLCEPNNK (15aa)
- QQQHLFGSNVTDC (13aa)
- QQQHLFGSNVTDCS (14aa)
- QQQHLFGSNVTDCSGNFC (18aa)
- QQQHLFGSNVTDCSGN (16aa)
- LFGSNVTDCSGNFCLFR (17aa)
- QQQHLFGSNVTDCSGNFCLF (20aa)
- QQQHLFGSNVTDCSGNFCLFR (21aa)
- QQQHLFGSNVTDCSGNF (17aa)
- QQQHLFGSNVTD (12aa)
- QQQHIFGSNVTDCSGNFCIFR (21aa)
- ILRQQQHLFGSNVTDCSGNFCLFR (24aa)
Mass spectrometry observed peptide
-
- O-Linked / Core 1 (avg mass : 383.3527)
- Amniotic Fluid (UBERON_0000173)
-
Serotransferrin / Homo sapiens
- Undefined site
-
- O-Linked / Core 1 (avg mass : 674.6106)
- Amniotic Fluid (UBERON_0000173)
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / No-core (avg mass : 894.8331)
- BTI-Tn-5B1-4 (CVCL_C190) Egg Cell
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / Pauci-Mannose (avg mass : 910.8325)
- BTI-Tn-5B1-4 (CVCL_C190) Egg Cell
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / Pauci-Mannose (avg mass : 1056.9755)
- BTI-Tn-5B1-4 (CVCL_C190) Egg Cell
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / Complex (avg mass : 1114.0275)
- BTI-Tn-5B1-4 (CVCL_C190) Egg Cell
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / Pauci-Mannose (avg mass : 1203.1185)
- BTI-Tn-5B1-4 (CVCL_C190) Egg Cell
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / High-Mannose (avg mass : 1235.1173)
- BTI-Tn-5B1-4 (CVCL_C190) Egg Cell
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / Complex (avg mass : 1260.1705)
- BTI-Tn-5B1-4 (CVCL_C190) Egg Cell
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / Complex (avg mass : 1260.1705)
- BTI-Tn-5B1-4 (CVCL_C190) Egg Cell
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / Complex (avg mass : 1276.1699)
- BTI-Tn-5B1-4 (CVCL_C190) Egg Cell
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / High-Mannose (avg mass : 1397.2597)
- BTI-Tn-5B1-4 (CVCL_C190) Egg Cell
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / High-Mannose (avg mass : 1397.2597)
- BTI-Tn-5B1-4 (CVCL_C190) Egg Cell
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / Complex (avg mass : 1422.3129)
- BTI-Tn-5B1-4 (CVCL_C190) Egg Cell
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / Complex (avg mass : 1479.3649)
- Serotransferrin / Homo sapiens
-
- N-Linked / High-Mannose (avg mass : 1559.4021)
- BTI-Tn-5B1-4 (CVCL_C190) Egg Cell
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / High-Mannose (avg mass : 1559.4021)
- BTI-Tn-5B1-4 (CVCL_C190) Egg Cell
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / Complex (avg mass : 1567.4278)
- Blood Serum (UBERON_0001977)
-
Serotransferrin / Homo sapiens
- Undefined site
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 1568.4559)
- BTI-Tn-5B1-4 (CVCL_C190) Egg Cell
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / Complex (avg mass : 1641.5073)
- Enrichment of glycopeptides for glycan structure and attachment site identification (2009 - Nilsson J, Rüetschi U, Halim A, Hesse C, Carlsohn E, Brinkmalm G, Larson G.) / Status : Reviewed
- Two-dimensional chromatography in the analysis of complex glycans from transferrin. (1998 - Charlwood J, Birrell H, Tolson D, Camilleri P) / Status : Reviewed
- Serotransferrin / Homo sapiens
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 1641.5073)
- Carcinoma, Hepatocellular (DOID:684)
- Two-dimensional chromatography in the analysis of complex glycans from transferrin. (1998 - Charlwood J, Birrell H, Tolson D, Camilleri P) / Status : Reviewed
- 'Brain-type' N-glycosylation of asialo-transferrin from human cerebrospinal fluid. (1995 - Hoffmann A, Nimtz M, Getzlaff R, Conradt H) / Status : Reviewed
- Alteration of asparagine-linked glycosylation in serum transferrin of patients with hepatocellular carcinoma. (1994 - Matsumoto K, Maeda Y, Kato S, Yuki H) / Status : Reviewed
-
Serotransferrin / Homo sapiens
- Undefined site
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 1666.5605)
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / High-Mannose (avg mass : 1721.5445)
- BTI-Tn-5B1-4 (CVCL_C190) Egg Cell
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / High-Mannose (avg mass : 1721.5445)
- BTI-Tn-5B1-4 (CVCL_C190) Egg Cell
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / Complex (avg mass : 1787.6503)
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / Complex (avg mass : 1787.6503)
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / Complex (avg mass : 1787.6503)
- Blood Serum (UBERON_0001977)
- Carcinoma, Hepatocellular (DOID:684)
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / Complex (avg mass : 1787.6503)
- Serotransferrin / Homo sapiens
-
- N-Linked / High-Mannose (avg mass : 1883.6869)
- BTI-Tn-5B1-4 (CVCL_C190) Egg Cell
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / Complex (avg mass : 1932.7652)
-
Serotransferrin / Homo sapiens
- Undefined site
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 1932.7652)
-
Serotransferrin / Homo sapiens
- Undefined site
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 1932.7652)
- Amniotic Fluid (UBERON_0000173)
-
Serotransferrin / Homo sapiens
- Undefined site
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 1932.7652)
-
Serotransferrin / Homo sapiens
- Undefined site
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 1990.8453)
- Blood Serum (UBERON_0001977)
- Carcinoma, Hepatocellular (DOID:684)
-
Serotransferrin / Homo sapiens
- Undefined site
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 2006.8447)
- Serotransferrin / Homo sapiens
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 2006.8447)
-
Serotransferrin / Homo sapiens
- Undefined site
- Serotransferrin / Homo sapiens
-
- N-Linked / High-Mannose (avg mass : 2045.8293)
- BTI-Tn-5B1-4 (CVCL_C190) Egg Cell
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / Complex (avg mass : 2078.9082)
- Amniotic Fluid (UBERON_0000173)
-
Serotransferrin / Homo sapiens
- Undefined site
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 2152.9877)
-
Serotransferrin / Homo sapiens
- Undefined site
-
- N-Linked / Complex (avg mass : 2224.0231)
-
Serotransferrin / Homo sapiens
- Undefined site
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 2224.0231)
- Amniotic Fluid (UBERON_0000173)
-
Serotransferrin / Homo sapiens
- Undefined site
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 2224.0231)
-
Serotransferrin / Homo sapiens
- Undefined site
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 2224.0231)
- Two-dimensional chromatography in the analysis of complex glycans from transferrin. (1998 - Charlwood J, Birrell H, Tolson D, Camilleri P) / Status : Reviewed
- Expression of N-linked sialyl Le(x) determinants and O-glycans in the carbohydrate moiety of human amniotic fluid transferrin during pregnancy. (1998 - van Rooijen J, Jeschke U, Kamerling J, Vliegenthart J) / Status : Reviewed
- N-glycosylation site mapping of human serotransferrin by serial lectin affinity chromatography, fast atom bombardment-mass spectrometry, and 1H nuclear magnetic resonance spectroscopy. (1992 - Fu D, van Halbeek H) / Status : Reviewed
- Serotransferrin / Homo sapiens
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 2298.1026)
-
Serotransferrin / Homo sapiens
- Undefined site
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 2370.1661)
-
Serotransferrin / Homo sapiens
- Undefined site
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 2370.1661)
- Amniotic Fluid (UBERON_0000173)
-
Serotransferrin / Homo sapiens
- Undefined site
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 2370.1661)
- Amniotic Fluid (UBERON_0000173)
-
Serotransferrin / Homo sapiens
- Undefined site
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 2370.1661)
- Amniotic Fluid (UBERON_0000173)
-
Serotransferrin / Homo sapiens
- Undefined site
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 2880.6184)
- Amniotic Fluid (UBERON_0000173)
-
Serotransferrin / Homo sapiens
- Undefined site
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 2880.6184)
- Expression of N-linked sialyl Le(x) determinants and O-glycans in the carbohydrate moiety of human amniotic fluid transferrin during pregnancy. (1998 - van Rooijen J, Jeschke U, Kamerling J, Vliegenthart J) / Status : Reviewed
- N-glycosylation site mapping of human serotransferrin by serial lectin affinity chromatography, fast atom bombardment-mass spectrometry, and 1H nuclear magnetic resonance spectroscopy. (1992 - Fu D, van Halbeek H) / Status : Reviewed
- Serotransferrin / Homo sapiens
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 2880.6184)
- Expression of N-linked sialyl Le(x) determinants and O-glycans in the carbohydrate moiety of human amniotic fluid transferrin during pregnancy. (1998 - van Rooijen J, Jeschke U, Kamerling J, Vliegenthart J) / Status : Reviewed
- N-glycosylation site mapping of human serotransferrin by serial lectin affinity chromatography, fast atom bombardment-mass spectrometry, and 1H nuclear magnetic resonance spectroscopy. (1992 - Fu D, van Halbeek H) / Status : Reviewed
- Serotransferrin / Homo sapiens
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 2880.6184)
- Amniotic Fluid (UBERON_0000173)
-
Serotransferrin / Homo sapiens
- Undefined site
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 3026.7614)
- Amniotic Fluid (UBERON_0000173)
-
Serotransferrin / Homo sapiens
- Undefined site
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 3026.7614)
- Amniotic Fluid (UBERON_0000173)
-
Serotransferrin / Homo sapiens
- Undefined site
- Serotransferrin / Homo sapiens
-
- N-Linked / Complex (avg mass : 3026.7614)
- Amniotic Fluid (UBERON_0000173)
-
Serotransferrin / Homo sapiens
- Undefined site
- Serotransferrin / Homo sapiens
-
- Hex:1 / O-Linked (avg mass : 180.1577)
- Serotransferrin / Homo sapiens
-
- Hex:4 HexNAc:3 NeuAc:1 / N-Linked (avg mass : 1567.4278)
- Blood Serum (UBERON_0001977)
- N-Linked / Complex / NeuAc(?2-?)Gal(?1-?)GlcNAc(?1-?)Man(a1-3)[Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- Prostate cancer (DOID:10283)
- Serotransferrin / Homo sapiens
- QQQHLFGSNVTDCSGNFCLFR (21aa)
-
- Hex:5 HexNAc:4 / N-Linked (avg mass : 1641.5073)
- N-Linked / Complex / Gal(?1-?)GlcNAc(?1-?)Man(a1-3)[Gal(?1-?)GlcNAc(?1-?)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- Cancer, breast (DOID:1612)
- Site-Specific Profiling of Serum Glycoproteins Using N-Linked Glycan and Glycosite Analysis Revealing Atypical N-Glycosylation Sites on Albumin and α-1B-Glycoprotein (2018 - Shisheng Sun, Yingwei Hu, Li Jia, Shadi Toghi Eshghi, Yang Liu, Punit Shah, Hui Zhang) / Status : Unreviewed
- Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
- Serotransferrin / Homo sapiens
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
- CGIVPVIAENYNK (13aa)
- CGLVPVLAENYNK (13aa)
- QQQHIFGSNVTDCSGNFCIFR (21aa)
- QQQHLFGSNVTDCSGNFCLFR (21aa)
-
- Hex:4 HexNAc:4 NeuAc:1 / N-Linked (avg mass : 1770.6228)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- Serotransferrin / Homo sapiens
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
-
- Hex:4 HexNAc:4 dHex:2 / N-Linked (avg mass : 1771.6509)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- Serotransferrin / Homo sapiens
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
-
- Hex:4 HexNAc:4 dHex:1 NeuAc:1 / N-Linked (avg mass : 1916.7658)
- Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
- Distinct urinary glycoprotein signatures in prostate cancer patients (2018 - Rebeca Kawahara, Fabio Ortega, Livia Rosa-Fernandes, Vanessa Guimarães, Daniel Quina, Willian Nahas, Veit Schwämmle, Miguel Srougi, Katia R.M. Leite, Morten Thaysen-Andersen, Martin R. Larsen and Giuseppe Palmisano) / Status : Unreviewed
- Serotransferrin / Homo sapiens
- CGIVPVIAENYNK (13aa)
- QQQHLFGSNVTDCSGNFCLFR (21aa)
-
- Hex:3 HexNAc:7 / N-Linked (avg mass : 1926.8075)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- Serotransferrin / Homo sapiens
- CGIVPVIAENYNK (13aa)
-
- Hex:5 HexNAc:4 NeuAc:1 / N-Linked (avg mass : 1932.7652)
- N-Linked / Complex / NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)Man(a1-6)[Gal(b1-4)GlcNAc(b1-2)Man(a1-3)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-?)[Gal(b1-4)GlcNAc(b1-2)Man(a1-?)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- Site-Specific Profiling of Serum Glycoproteins Using N-Linked Glycan and Glycosite Analysis Revealing Atypical N-Glycosylation Sites on Albumin and α-1B-Glycoprotein (2018 - Shisheng Sun, Yingwei Hu, Li Jia, Shadi Toghi Eshghi, Yang Liu, Punit Shah, Hui Zhang) / Status : Unreviewed
- Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
- Large-scale intact glycopeptide identification by Mascot database search (2018 - Ravi Chand Bollineni, Christian Jeffrey Koehler, Randi Elin Gislefoss, Jan Haug Anonsen, Bernd Thiede) / Status : Unreviewed
- Distinct urinary glycoprotein signatures in prostate cancer patients (2018 - Rebeca Kawahara, Fabio Ortega, Livia Rosa-Fernandes, Vanessa Guimarães, Daniel Quina, Willian Nahas, Veit Schwämmle, Miguel Srougi, Katia R.M. Leite, Morten Thaysen-Andersen, Martin R. Larsen and Giuseppe Palmisano) / Status : Unreviewed
- Simultaneous glycosylation analysis of human serum glycoproteins by high-performance liquid chromatography/tandem mass spectrometry (2008 - Harazono A, Kawasaki N, Itoh S, Hashii N, Matsuishi-Nakajima Y, Kawanishi T, Yamaguchi T) / Status : Reviewed
- Serotransferrin / Homo sapiens
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVKK (33aa)
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVKK (33aa)
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
- CGIVPVIAENYNK (13aa)
- CGLVPVLAENYNK (13aa)
- KCGLVPVLAENYNK (14aa)
- QQQHIFGSNVTDCSGNFCIFR (21aa)
- QQQHLFGSNVTDCSGN (16aa)
- QQQHLFGSNVTDCSGNFCLF (20aa)
- QQQHLFGSNVTDCSGNFCLFR (21aa)
- QQQHLFGSNVTDCSGNF (17aa)
-
- Hex:4 HexNAc:6 dHex:1 / N-Linked (avg mass : 2031.8979)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- Serotransferrin / Homo sapiens
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
-
- Hex:4 HexNAc:4 dHex:2 NeuAc:1 / N-Linked (avg mass : 2062.9088)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- Serotransferrin / Homo sapiens
- CGIVPVIAENYNK (13aa)
- QQQHIFGSNVTDCSGNFCIFR (21aa)
-
- Hex:5 HexNAc:4 dHex:1 NeuAc:1 / N-Linked (avg mass : 2078.9082)
- N-Linked / Complex / NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc
- Cancer, breast (DOID:1612)
- Site-Specific Profiling of Serum Glycoproteins Using N-Linked Glycan and Glycosite Analysis Revealing Atypical N-Glycosylation Sites on Albumin and α-1B-Glycoprotein (2018 - Shisheng Sun, Yingwei Hu, Li Jia, Shadi Toghi Eshghi, Yang Liu, Punit Shah, Hui Zhang) / Status : Unreviewed
- Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
- Serotransferrin / Homo sapiens
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
- CGIVPVIAENYNK (13aa)
- QQQHIFGSNVTDCSGNFCIFR (21aa)
- QQQHLFGSNVTDCSGNFCLFR (21aa)
- QQQHLFGSNVTDCSGNF (17aa)
-
- Hex:3 HexNAc:6 dHex:1 NeuAc:1 / N-Linked (avg mass : 2161.0134)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- Serotransferrin / Homo sapiens
- CGLVPVLAENYNK (13aa)
-
- Hex:4 HexNAc:6 dHex:2 / N-Linked (avg mass : 2178.0409)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- Serotransferrin / Homo sapiens
- CGIVPVIAENYNK (13aa)
- KCGLVPVLAENYNK (14aa)
-
- Hex:5 HexNAc:4 NeuAc:2 / N-Linked (avg mass : 2224.0231)
- Blood Plasma (UBERON_0001969)
- Blood Serum (UBERON_0001977)
- Mammary Gland (UBERON_0001911)
- Urine (UBERON_0001088)
- N-Linked / Complex / NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)Man(a1-6)[NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-3)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)Man(a1-?)[NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-?)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- N-Linked / Complex / NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[NeuAc(a2-6)Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- Site-Specific Profiling of Serum Glycoproteins Using N-Linked Glycan and Glycosite Analysis Revealing Atypical N-Glycosylation Sites on Albumin and α-1B-Glycoprotein (2018 - Shisheng Sun, Yingwei Hu, Li Jia, Shadi Toghi Eshghi, Yang Liu, Punit Shah, Hui Zhang) / Status : Unreviewed
- Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
- Large-scale intact glycopeptide identification by Mascot database search (2018 - Ravi Chand Bollineni, Christian Jeffrey Koehler, Randi Elin Gislefoss, Jan Haug Anonsen, Bernd Thiede) / Status : Unreviewed
- Distinct urinary glycoprotein signatures in prostate cancer patients (2018 - Rebeca Kawahara, Fabio Ortega, Livia Rosa-Fernandes, Vanessa Guimarães, Daniel Quina, Willian Nahas, Veit Schwämmle, Miguel Srougi, Katia R.M. Leite, Morten Thaysen-Andersen, Martin R. Larsen and Giuseppe Palmisano) / Status : Unreviewed
- Selective glycopeptide profiling by acetone enrichment and LC/MS (2014 - Takakura D, Harazono A, Hashii N, Kawasaki N) / Status : Reviewed
- Comparison of sialylated N-glycopeptide levels in serum of pancreatic cancer patients, acute pancreatitis patients, and healthy controls (2014 - Kontro H, Joenväärä S, Haglund C, Renkonen R) / Status : Reviewed
- Confident assignment of site-specific glycosylation in complex glycoproteins in a single step (2014 - Khatri K, Staples GO, Leymarie N, Leon DR, Turiák L, Huang Y, Yip S, Hu H, Heckendorf CF, Zaia J.) / Status : Reviewed
- Glycomic analysis of high density lipoprotein shows a highly sialylated particle (2014 - Huang J1, Lee H, Zivkovic AM, Smilowitz JT, Rivera N, German JB, Lebrilla CB) / Status : Reviewed
- Simultaneous glycosylation analysis of human serum glycoproteins by high-performance liquid chromatography/tandem mass spectrometry (2008 - Harazono A, Kawasaki N, Itoh S, Hashii N, Matsuishi-Nakajima Y, Kawanishi T, Yamaguchi T) / Status : Reviewed
- Serotransferrin / Homo sapiens
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVKK (33aa)
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVKK (33aa)
- CGIVPVIAENYNK (13aa)
- KCGLVPVLAENYNK (14aa)
- CGLVPVLAENYNK (13aa)
- LAENYNK (7aa)
- GLVPVLAENYNK (12aa)
- CGLVPVLAENYNKSDNCEDTPEAGYF (26aa)
- LCMGSGLNLCEPNNK (15aa)
- QQQHLFGSNVTDC (13aa)
- QQQHLFGSNVTDCS (14aa)
- QQQHLFGSNVTDCSGNFC (18aa)
- QQQHLFGSNVTDCSGN (16aa)
- LFGSNVTDCSGNFCLFR (17aa)
- QQQHLFGSNVTDCSGNFCLF (20aa)
- QQQHLFGSNVTDCSGNFCLFR (21aa)
- QQQHLFGSNVTDCSGNF (17aa)
- QQQHLFGSNVTD (12aa)
- QQQHIFGSNVTDCSGNFCIFR (21aa)
- ILRQQQHLFGSNVTDCSGNFCLFR (24aa)
-
- Hex:5 HexNAc:4 NeuAc:1 NeuGc:1 / N-Linked (avg mass : 2240.0225)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- Serotransferrin / Homo sapiens
- CGLVPVLAENYNK (13aa)
-
- Hex:4 HexNAc:5 dHex:2 NeuAc:1 / N-Linked (avg mass : 2266.1038)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- Serotransferrin / Homo sapiens
- CGIVPVIAENYNK (13aa)
- QQQHIFGSNVTDCSGNFCIFR (21aa)
-
- Hex:12 HexNAc:2 / N-Linked (avg mass : 2370.1141)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- Serotransferrin / Homo sapiens
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVKK (33aa)
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVKK (33aa)
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
- CGIVPVIAENYNK (13aa)
- KCGLVPVLAENYNK (14aa)
- QQQHIFGSNVTDCSGNFCIFR (21aa)
- QQQHLFGSNVTDCSGNFCLF (20aa)
-
- Hex:3 HexNAc:6 dHex:1 NeuAc:2 / N-Linked (avg mass : 2452.2713)
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- Serotransferrin / Homo sapiens
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
- QQQHLFGSNVTDCSGNFCLFR (21aa)
-
- Hex:4 HexNAc:5 NeuAc:1 NeuGc:1 / N-Linked
- Urine (UBERON_0001088)
- Prostate cancer (DOID:10283)
- Serotransferrin / Homo sapiens
- CGLVPVLAENYNK (13aa)
-
- Hex:4 HexNAc:9 / N-Linked
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- Serotransferrin / Homo sapiens
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
-
- Hex:6 HexNAc:4 dHex:1 / N-Linked (avg mass : 1949.7927)
- Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
- Distinct urinary glycoprotein signatures in prostate cancer patients (2018 - Rebeca Kawahara, Fabio Ortega, Livia Rosa-Fernandes, Vanessa Guimarães, Daniel Quina, Willian Nahas, Veit Schwämmle, Miguel Srougi, Katia R.M. Leite, Morten Thaysen-Andersen, Martin R. Larsen and Giuseppe Palmisano) / Status : Unreviewed
- Serotransferrin / Homo sapiens
- CGIVPVIAENYNK (13aa)
- CGLVPVLAENYNK (13aa)
- QQQHIFGSNVTDCSGNFCIFR (21aa)
-
- Hex:5 HexNAc:5 dHex:1 / N-Linked (avg mass : 1990.8453)
- Mammary Gland (UBERON_0001911)
- N-Linked / Complex / Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[Gal(b1-4)GlcNAc(b1-2)Man(a1-6)][GlcNAc(b1-4)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc
- Cancer, breast (DOID:1612)
- Serotransferrin / Homo sapiens
- QQQHIFGSNVTDCSGNFCIFR (21aa)
-
- Hex:6 HexNAc:5 / N-Linked (avg mass : 2006.8447)
- Mammary Gland (UBERON_0001911)
- N-Linked / Complex / Gal(?1-?)GlcNAc(?1-?)[Gal(?1-?)GlcNAc(?1-?)]Man(a1-?)[Gal(?1-?)GlcNAc(?1-?)Man(a1-?)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- Cancer, breast (DOID:1612)
- Serotransferrin / Homo sapiens
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
- CGIVPVIAENYNK (13aa)
-
- Hex:6 HexNAc:4 NeuAc:1 / N-Linked (avg mass : 2094.9076)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- Serotransferrin / Homo sapiens
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
- CGLVPVLAENYNKSDNCEDTPEAGYFAVAVVK (32aa)
- CGIVPVIAENYNK (13aa)
- QQQHIFGSNVTDCSGNFCIFR (21aa)
-
- Hex:6 HexNAc:4 dHex:2 / N-Linked (avg mass : 2095.9357)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- Serotransferrin / Homo sapiens
- CGIVPVIAENYNK (13aa)
-
- Hex:5 HexNAc:5 NeuAc:1 / N-Linked (avg mass : 2135.9602)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
-
Serotransferrin / Homo sapiens
Source
Suggested structure
Disease
Reported glycosite
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Suggested structure
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Suggested structure
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Suggested structure
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Disease
Reference
Reported glycosite
Suggested glycosite
Disease
Reference
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Disease
Reference
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Disease
Reported glycosite
Suggested glycosite
Disease
Reference
Reported glycosite
Suggested glycosite
Disease
Reference
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite
Source
Disease
Reported glycosite
Suggested glycosite